List of IDBS Polar Customers
Woking, GU21 5BJ, Surrey,
United Kingdom
Since 2010, our global team of researchers has been studying IDBS Polar customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased IDBS Polar for Life Science R&D Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using IDBS Polar for Life Science R&D Platforms include: Iqvia, a United States based Professional Services organisation with 88000 employees and revenues of $15.41 billion, KBI Biopharma, a United States based Life Sciences organisation with 1754 employees and revenues of $425.0 million, PharmaEssentia, a Taiwan based Life Sciences organisation with 500 employees and revenues of $158.0 million, PharmaEssentia United States, a United States based Life Sciences organisation with 40 employees and revenues of $30.0 million and many others.
Contact us if you need a completed and verified list of companies using IDBS Polar, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The IDBS Polar customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Iqvia | Professional Services | 88000 | $15.4B | United States | IDBS | IDBS Polar | Life Science R&D Platforms | 2010 | n/a | In 2010, IQVIA implemented IDBS Polar as part of its laboratory informatics portfolio, leveraging the application within the Life Science R&D Platforms category to support bioanalytical operations. IQVIA Laboratories has publicly presented platform-led initiatives that reference IDBS solutions, documenting efforts in bioanalytical template development and GxP system validation across its US lab network. IDBS Polar was applied to standardize test templates and drive digital innovation in laboratory workflows, with module-level use inferred from IQVIA’s long-standing adoption of IDBS informatics and participation in customer presentations. Typical functional capabilities aligned to the deployment include test template management, structured data capture for bioanalytical assays, and compliance-oriented configuration to support GxP validation activities. The implementation covered IQVIA’s laboratories in the United States, providing a consistent platform for lab network standardization and operational alignment of bioanalytical functions. Platform components were used to harmonize laboratory practices and instrumentation-facing data capture workflows, supporting centralized template provisioning and reproducible assay execution across sites. Governance and rollout emphasized validated GxP processes and standardized template governance, reflecting IQVIA’s public disclosures of validation activities and template development work. IDBS Polar served as the instrument for organizing laboratory test templates and compliance controls, enabling IQVIA Laboratories to present a coherent, platform-led approach to lab informatics and quality governance. | |
 |
KBI Biopharma | Life Sciences | 1754 | $425M | United States | IDBS | IDBS Polar | Life Science R&D Platforms | 2022 | n/a | In 2022, KBI Biopharma implemented IDBS Polar as part of its Life Science R&D Platforms stack to standardize electronic laboratory notebook data capture and support CDMO reporting workflows. The deployment of IDBS Polar is positioned to provide enterprise laboratory informatics capabilities across research and development and outsourced development services for clients. Implementation centered on standardizing ELN capture and consolidating laboratory outputs, with IDBS Polar used to normalize experimental data and instrument-derived records. Module-level usage of IDBS Polar is inferred from KBI's adoption of IDBS laboratory informatics components and IDBS' positioning of Polar as an enterprise lab platform, indicating use of ELN-aligned capture, structured data management, and laboratory workflow coordination features. KBI Biopharma uses IDBS as a data source for its PROGRAMview client portal, integrating IDBS Polar outputs into a centralized data lake and providing near-real-time client access to study outputs. The integration chain explicitly includes PROGRAMview for client-facing delivery and a data lake for centralized analytics and reporting, supporting reporting activities within KBI's CDMO operations. Platform usage at KBI is documented in IDBS event materials, and the operational rollout emphasized standardized capture and centralized output flows to support client transparency. KBI reports an estimated approximately 2,500 hours saved per year across reporting activities as a result of standardizing ELN data capture and centralizing outputs through IDBS Polar and its associated data pipeline. | |
 |
PharmaEssentia | Life Sciences | 500 | $158M | Taiwan | IDBS | IDBS Polar | Life Science R&D Platforms | 2024 | n/a | In 2024, PharmaEssentia implemented IDBS Polar as a Life Science R&D Platforms solution to enable collaboration between its new Innovation Research Center in Boston and its Taipei R&D organization. The Boston PIRC deployment will onboard an initial 15 users expanding to 25 users, with a subsequent onboarding of about 65 Taipei users who will be securely connected to the Boston instance to create a unified data environment. The implementation emphasizes electronic laboratory notebook capability that extends beyond traditional ELN functionality, delivering structured data capture, experiment record keeping, and a single chain of custody for experimental data. IDBS Polar was selected for its multi-language capability including Mandarin, and for platform capabilities that include dynamic inventory management directly tied to experimental workflows, with scope to expand into AI ML analytics and reporting. Operational coverage centers on laboratory R&D workflows across discovery and early development functions, aligning experimental protocols, materials and sample tracking between sites. The deployment configures inventory management inside experimental workflows so that equipment, materials and samples can be tracked dynamically as part of the scientific process, preserving provenance and enabling cross-site data interrogation. PharmaEssentia executed a phased rollout with training and demonstrations to address cultural and process change in the Taipei team that had been using paper records, which helped accelerate adoption. Governance practices reflect a single source of truth approach, standardized experiment documentation and collaborative workflows to support learning from both successful and failed experiments, and future expansion into analytics and reporting as platform usage grows. | |
 |
|
Life Sciences | 40 | $30M | United States | IDBS | IDBS Polar | Life Science R&D Platforms | 2024 | n/a |
|
|
Buyer Intent: Companies Evaluating IDBS Polar
- Newport Financial Group, a United States based Banking and Financial Services organization with 40 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||